KLRD1 and Miyoshi myopathy: The accumulation of CD94lowCD56dim NK cell subset in the early phase of disease provides rationale for employing NK cell-based therapeutic strategies in early stages of MM and highlights the importance of strategies supporting expansion and infusion of CD94/NKG2A− NK cells [26].